When anti-TNF fails, anti-IL12-23 is an alternate option in psoriasis and psoriatic arthritis

Abstract Patients with psoriasis and psoriatic arthritis respond to anti-TNF therapy, but not all pa- tients maintain effective response, and some do not respond. In this article, we demon- strate the role of a new pathogenetic pathway to some extent TNF-independent in these patients. Anti-IL12-23 is a new and alternate mode of therapy for patients with recalcitrant response to anti-TNF.